About Embla Medical

Sveinn Sölvason, President and CEO, comments:

"Sales in Q3 2025 amounted to USD 237 million, representing 11% reported growth, of which 7% was organic.

Growth picked up in the third quarter as expected, driven by double-digit growth in Prosthetics & Neuro Orthotics. The solid momentum in EMEA continues and growth in Americas was strong following a soft start to the year, supported by our recently launched innovations.

The EBITDA margin was strong at 22% in Q3 2025 and 21% for the first nine months of the year compared to 20% (before special items) in the comparable period. In line with our performance recorded in the first nine months of 2025, our guidance for the full-year 2025 has been reiterated"

Embla will host a conference call on Oct 21, 2025 at 09:00 CET / 7:00 GMT / 3:00 EST. Please visit our Investor Relations section for further information.

We serve our investors, by communicating in an informative and honest way. We are ambitious about the way we interact. It is our policy to provide investors, analysts and other stakeholders with comprehensive and accurate information to improve the understanding of the current and expected development of Embla Medical.